Dr. Shuchi Gulati, MD FACP
Claim this profileUniversity of Cincinnati Medical Center
Studies Cancer
Studies Tumors
13 reported clinical trials
26 drugs studied
Area of expertise
1Cancer
Stage IV
Stage III
FGFR2 positive
2Tumors
Stage IV
Stage III
ARID1A positive
Affiliated Hospitals
Clinical Trials Shuchi Gulati, MD FACP is currently running
Cabozantinib +/− Atezolizumab
for Advanced Kidney Cancer
This phase II trial compares the effect of atezolizumab in combination with usual treatment with cabozantinib to cabozantinib alone in patients with papillary renal cell carcinoma that has spread to other places in the body (metastatic). Papillary renal cell carcinoma (PRCC) is a type of kidney cancer that forms in the lining of the tiny tubes in the kidney that return filtered substances that the body needs back to the blood and remove extra fluid and waste as urine. Most papillary tumors look like long, thin finger-like growths under a microscope. It is also called papillary kidney cancer or PRCC. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Cabozantinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply and may also prevent the growth of new blood vessels that tumors need to grow. By these actions it may help slow or stop the spread of cancer cells. Combination therapy with atezolizumab and cabozantinib may shrink the cancer and allow a longer survival time in patients with metastatic renal cell carcinoma.
Recruiting1 award Phase 230 criteria
Radium-223 + Docetaxel
for Prostate Cancer
The purpose of this study is to compare any good and bad effects of using radium-223 along with docetaxel chemotherapy treatment versus using docetaxel alone. Earlier studies helped show that the combination is safe, but the combination has not been proven to work better than either drug alone. The goal of this study is to find out if combining docetaxel and radium-223 is better than giving either drug by itself.
Recruiting2 awards Phase 323 criteria
More about Shuchi Gulati, MD FACP
Clinical Trial Related4 years of experience running clinical trials · Led 13 trials as a Principal Investigator · 8 Active Clinical TrialsTreatments Shuchi Gulati, MD FACP has experience with
- Pembrolizumab
- Nivolumab
- Ipilimumab
- ONC-392
- Biospecimen Collection
- Cabozantinib S-malate
Breakdown of trials Shuchi Gulati, MD FACP has run
Cancer
Tumors
Prostate Cancer
Renal Cell Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Shuchi Gulati, MD FACP specialize in?
Shuchi Gulati, MD FACP focuses on Cancer and Tumors. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are Stage III.
Is Shuchi Gulati, MD FACP currently recruiting for clinical trials?
Yes, Shuchi Gulati, MD FACP is currently recruiting for 7 clinical trials in Cincinnati Ohio. If you're interested in participating, you should apply.
Are there any treatments that Shuchi Gulati, MD FACP has studied deeply?
Yes, Shuchi Gulati, MD FACP has studied treatments such as Pembrolizumab, Nivolumab, Ipilimumab.
What is the best way to schedule an appointment with Shuchi Gulati, MD FACP?
Apply for one of the trials that Shuchi Gulati, MD FACP is conducting.
What is the office address of Shuchi Gulati, MD FACP?
The office of Shuchi Gulati, MD FACP is located at: University of Cincinnati Medical Center, Cincinnati, Ohio 45219 United States. This is the address for their practice at the University of Cincinnati Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.